A powder formulation, or pharmaceutical composition comprising or consisting of particles of an antimuscarinic agent, said particles being obtainable by supercritical anti-solvent (SAS) precipitation and having a D50 of 4 μm or less and a D90 of 10 μm or less. Methods of forming the formulation and composition are also disclosed, as are uses of the composition.